News | March 24, 2026
Bayer wins world-first nod in Japan for low-dose MRI contrast agent
Call it a major breakthrough for diagnostic imaging
Call it a major breakthrough for diagnostic imaging
The system also introduces Imaging Scanner Interface 2 (ISI2) capability, enabling direct communication between injector and scanner to improve exam coordination and operational efficiency
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke
The partnership initially will focus on cardiovascular and kidney diseases
Favorable outcome would contribute to significantly containing the Roundup litigation as the company continues its multi-pronged strategy
The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology
The collaboration centers on the "Life Doesn't Stop for a Hot Flash" campaign
The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics
Sevabertinib is an oral, reversible tyrosine kinase inhibitor (TKI) that directly targets HER2 mutations
Subscribe To Our Newsletter & Stay Updated
